1. To observe and compare the overall response rate (ORR) of baseline BEACOPP and ABVD regimens for patients with advanced Hodgkin's lymphoma.
2. To evaluate the safety of Natulan® in Chinese patients with advanced Hodgkin's lymphoma

This is a confirmatory open-label, randomized, controlled, multicenter study. Recruited subjects are to be randomized to treatment group and controlled group, with ratio of 1:1. Treatment group will accept baseline BEACOPP regimen, while controlled group will accept ABVD regimen.

The study design consisted of a screening phase of 1 week, a treatment phase of 24 or 32 weeks, and a post treatment follow-up of at least 2 years.

Inclusion Criteria:

• The subject is of age 18~65, both male and female;
• Newly pathologically diagnosed with classical Hodgkin's lymphoma (lymphocyte depletion type, lymphocyte rich type, nodular sclerosing type, and mixed cellularity type), who had not accepted previous treatment;
• Had stage IIB, III or IV disease, as assessed by the Ann Arbor classification;
• ECOG≤2, life expectancy ≥3 month;
• A negative serum pregnancy test required for sexually active women of childbearing potential;
• The subject voluntarily gives written informed consent to participate in the study.

Exclusion Criteria:

• Hematopoietic function:

  • Leukocyte <3,500/mm3（3.5×109/L）
  • Neutrophils <1,500/mm3（1.5×109/L）
  • Platelets <100,000/mm3（100×109/L）

• Intolerance to any of the active ingredients and/or excipients in the study medications;

• Severe central nervous system disorders and mental illness;

• Severe heart disease (congestive heart failure, uncontrolled hypertension, unstable coronary artery disease, or myocardial infarction, or severe arrhythmia). Echocardiography showed resting left ventricular ejection fraction (LVEF) < 50%);

• History of severe lung disease;

• AST or ALT>2.5×ULN，total bilirubin≥1.5×ULN，serum creatinine>1.5×ULN (for subject with liver metastases: AST or ALT>5xULN, total bilirubin ≥ 3xULN);

• Uncontrolled, systemic, active infection；

• Positive serology to HIV;

• HBsAg positive subjects can still be enrolled in the study, but researchers should follow "The consensus on the Treatment of Lymphoma with Hepatitis B Infections" to observe closely and/or provide prophylactic anti-HBV therapy (as per investigator's decision);

• Other previous or concomitant malignancy, except for basal cell carcinoma and/or cervical carcinoma in situ;

• The subject is receiving an investigational drug, or has participated in an investigational study within 30 days prior to screening;

• The subject is pregnant or lactating; or subjects of childbearing potential (both women and man subjects) do not want to take effective contraceptive measures during study period or within 3 months after study completes;

• Investigators believe subjects not suitable to participate in the study for other reasons.